<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909333</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00169; qu20Antwi2</org_study_id>
    <nct_id>NCT04909333</nct_id>
  </id_info>
  <brief_title>Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia</brief_title>
  <acronym>FAST</acronym>
  <official_title>Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gottfried und Julia Bangerter-Rhyner-Stiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the concept of the exenatide test for diagnosis of EHH (earlier&#xD;
      induction of symptomatic hypoglycemia compared to placebo within 4 hours after injection).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endogenous hyperinsulinemic hypoglycemia (EHH) is defined as inappropriate endogenous insulin&#xD;
      secretion leading to hypoglycemia and associated symptoms. The most frequent diagnosis is an&#xD;
      insulin-secreting pancreatic neuroendocrine tumor, but other diagnoses such as&#xD;
      nesidioblastosis of the pancreatic islets are also possible. Biochemically, EHH is&#xD;
      characterized by low glucose concentrations in the presence of inappropriately increased&#xD;
      C-peptide (endogenous insulin secretion) and insulin levels. The conventional fasting test is&#xD;
      at present the gold standard to document EHH.&#xD;
&#xD;
      Radiolabeled Exenatide for localizing insulinomas in patients with biochemically proven EHH&#xD;
      has been evaluated and an exenatide-test in an outpatient setting may be able to replace the&#xD;
      fasting test, by an early symptomatic hypoglycemia compared to a prolonged inpatient&#xD;
      monitoring.&#xD;
&#xD;
      This study is to investigate the concept of the exenatide test to diagnose EHH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to symptomatic hypoglycemia after exenatide test compared to placebo</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>time to symptomatic hypoglycemia after exenatide test compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time dependent decrease (time Δ from injection in min) of blood glucose (% or mmol/l))</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>time dependent decrease (time Δ from injection in min) of blood glucose (% or mmol/l)) that can best discriminate from placebo injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to symptoms</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>time to symptoms of the exenatide test in comparison to the placebo injection of 10ml 0.9% saline solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to hypoglycemia (time to reach blood sugar level ≤ 2.5 mmol/l) in the exenatide test in comparison to the placebo</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>time to hypoglycemia (time to reach blood sugar level ≤ 2.5 mmol/l) in the exenatide test in comparison to the placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to hypoglycemia (time to reach blood sugar level ≤ 2.5 mmol/l) in the exenatide test in comparison to the fasting test</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>time to hypoglycemia (time to reach blood sugar level ≤ 2.5 mmol/l) in the exenatide test in comparison to the fasting test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to symptoms in the exenatide test in comparison to the fasting test</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>time to symptoms in the exenatide test in comparison to the fasting test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in levels of plasma glucose compared to placebo compared to placebo</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>change in levels of plasma glucose compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in levels of insulin compared to placebo</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>change in levels of insulin compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in levels of C-peptide compared to placebo</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>change in levels of C-peptide compared to placebo compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in levels of proinsulin compared to placebo</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>change in levels of proinsulin compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in levels of ß-hydroxybutyrate compared to placebo</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>change in levels of ß-hydroxybutyrate compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>costs of exenatide test setting (CHF)</measure>
    <time_frame>within 4 hours after injection</time_frame>
    <description>Comparison of costs of exenatide test setting with fasting test setting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Endogenous Hyperinsulinism</condition>
  <arm_group>
    <arm_group_label>Group A (EHH Patients)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A will receive a placebo injection (0.9% saline solution) on Day 1 and 10μg Exenatide injection on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (EHH Patients)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B will receive a 10μg Exenatide injection on Day 1 and placebo injection (0.9% saline solution) on Day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 5 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.&#xD;
Day2:&#xD;
The procedure is equal to study day 1. Instead of Exenatide a 10ml 0.9% saline solution, will be administered intravenously.</description>
    <arm_group_label>Group A (EHH Patients)</arm_group_label>
    <arm_group_label>Group B (EHH Patients)</arm_group_label>
    <other_name>Day 1 Exenatide; Day 2 : 0.9% saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% saline solution</intervention_name>
    <description>Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 5 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.&#xD;
Day2:&#xD;
The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously.</description>
    <arm_group_label>Group A (EHH Patients)</arm_group_label>
    <arm_group_label>Group B (EHH Patients)</arm_group_label>
    <other_name>Day 1 : 0.9% saline solution, Day 2 Exenatide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
          -  Biochemically proven endogenous hyperinsulinemic hypoglycemia: neuroglycopenic&#xD;
             symptoms in the fasting state with low plasma glucose, inappropriately high serum&#xD;
             insulin and C-peptide concentrations (standardized 72h fasting test).).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or allergy to Exenatide&#xD;
&#xD;
          -  Pregnant or breastfeeding female patients. A pregnancy test will be performed in all&#xD;
             women of child bearing potential.&#xD;
&#xD;
          -  Calculated creatinine clearance below 40 ml/min&#xD;
&#xD;
          -  No signed informed consent&#xD;
&#xD;
          -  Intake of any GLP-1 analogue (such as Byetta® or Bydureon®[= Exenatide])&#xD;
&#xD;
          -  prediabetes or diabetes (HbA1c &gt; 5.7 %)&#xD;
&#xD;
          -  Previous abdominal surgery in the gastrointestinal tract&#xD;
&#xD;
          -  Any concomitant glucose-lowering drug (i. e. insulin, sulfonyl urea)&#xD;
&#xD;
          -  Any known intolerance to standardized meal (Maizena)&#xD;
&#xD;
          -  Any uncontrolled significant medical, psychiatric or surgical condition (active&#xD;
             infection, unstable angina pectoris, cardiac arrhythmia, poorly controlled&#xD;
             hypertension, uncontrolled congestive heart disease, etc.) or laboratory findings that&#xD;
             might jeopardize the patient's safety or that would limit compliance with the&#xD;
             objectives and assessments of the study.&#xD;
&#xD;
          -  Any mental conditions which prevent the patient from understanding the type, extent&#xD;
             and possible consequences of the study and/or an uncooperative attitude from the&#xD;
             patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuel Christ, Prof. Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Basel, Interdisciplinary Endocrinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kwadwo Antwi, Dr. med.</last_name>
    <phone>+41 61 32 86684</phone>
    <email>Kwadwo.Antwi@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Basel, Division of Nuclear Medicine</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwadwo Antwi, Dr. med.</last_name>
      <phone>+41 61 32 86684</phone>
      <email>Kwadwo.Antwi@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Kwadwo Antwi, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Hepprich, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damian Wild, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Kaul, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tobias Heye, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuel Christ, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fasting test</keyword>
  <keyword>Blood glucose</keyword>
  <keyword>insulin</keyword>
  <keyword>proinsulin</keyword>
  <keyword>C-peptide</keyword>
  <keyword>betahydroxybutyrate</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

